Why the study?
Does right ventricular ejection fraction (RVEF) measured by radionuclide angiography predict survival in patients with pulmonary arterial hypertension?
Does right ventricular ejection fraction (RVEF) measured by radionuclide angiography predict survival in patients with pulmonary arterial hypertension?
Answers are grounded in this paper and cite their sources.
Right ventricular ejection fraction is a critical prognostic marker in pulmonary arterial hypertension, emphasizing that the disease is characterized by RV-arterial uncoupling rather than solely pulmonary vascular remodeling.
In the present issue of the European Respiratory Journal , Courand et al. [1] report on the prognostic relevance of radionuclide angiography of the right ventricle (RV) in a cohort of 100 patients with idiopathic, heritable or drug-related pulmonary arterial hypertension (PAH). Patients with a baseline RV ejection fraction (RVEF) >25% had better survival than those with a RVEF <25%. Furthermore, patients with a stable or increased RVEF at 3–6 months had a trend to better overall survival and a significantly lower cardiovascular mortality. These results are in keeping with recently demonstrated prognostic relevance of baseline and follow-up RVEF, but measured by magnetic resonance imaging (MRI) in PAH patients [2]. A striking finding in both studies was the dissociation between RVEF and pulmonary vascular resistance (PVR). Thus, a decreased PVR under targeted therapies could be associated with either deterioration or improvement in RV function [1, 2]. The notion emerges that PAH is a disease of RV–arterial uncoupling rather than only of pathological pulmonary vascular remodelling [3]. Decreased RVEF and PVR is associated with a decreased survival rate in PAH patients under targeted therapies <http://ow.ly/EBK8U>
No takes yet. Share an insight, caveat, or question.
Naeije et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: